David E. Gerber
About
David E. Gerber is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Public Health, Environmental and Occupational Health.
According to data from OpenAlex, David E. Gerber has authored 292 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 161 papers in Oncology, 138 papers in Pulmonary and Respiratory Medicine and 39 papers in Public Health, Environmental and Occupational Health. Recurrent topics in David E. Gerber's work include Lung Cancer Treatments and Mutations (114 papers), Cancer Immunotherapy and Biomarkers (61 papers) and Lung Cancer Diagnosis and Treatment (57 papers). David E. Gerber is often cited by papers focused on Lung Cancer Treatments and Mutations (114 papers), Cancer Immunotherapy and Biomarkers (61 papers) and Lung Cancer Diagnosis and Treatment (57 papers). David E. Gerber collaborates with scholars based in United States, Canada and China. David E. Gerber's co-authors include Lorraine Pelosof, Yang Xie, Joan H. Schiller, John D. Minna, Julie R. Brahmer, Sandi L. Pruitt, Scott Gettinger, Shaheen Khan, Laura Q.M. Chow and Scott Antonia and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.
In The Last Decade
David E. Gerber
277 papers receiving 9.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| David E. Gerber United States | 49 | 5.4k | 4.4k | 1.8k | 1.2k | 1.1k | 292 | 9.6k | ||
| Bhumsuk Keam South Korea | 50 | 6.1k 1.1× | 4.0k 0.9× | 2.1k 1.2× | 1.2k 1.0× | 1.6k 1.4× | 373 | 9.9k | ||
| Sumithra J. Mandrekar United States | 47 | 4.3k 0.8× | 3.4k 0.8× | 1.8k 1.0× | 782 0.6× | 1.4k 1.2× | 213 | 9.4k | ||
| Taofeek K. Owonikoko United States | 52 | 5.8k 1.1× | 3.4k 0.8× | 3.8k 2.1× | 1.6k 1.3× | 1.4k 1.2× | 326 | 10.7k | ||
| Rajeshwari Sridhara United States | 53 | 4.8k 0.9× | 2.9k 0.6× | 3.0k 1.7× | 788 0.6× | 1.3k 1.2× | 137 | 9.3k | ||
| Joachim G.J.V. Aerts Netherlands | 53 | 4.9k 0.9× | 5.5k 1.2× | 2.0k 1.1× | 2.0k 1.7× | 1.0k 0.9× | 341 | 10.6k | ||
| Stephen V. Liu United States | 42 | 4.2k 0.8× | 2.5k 0.6× | 1.7k 0.9× | 619 0.5× | 1.1k 1.0× | 341 | 6.9k | ||
| Jeffrey Crawford United States | 48 | 6.8k 1.3× | 2.8k 0.6× | 1.4k 0.8× | 581 0.5× | 731 0.6× | 206 | 10.2k | ||
| Zhengjia Chen United States | 51 | 3.1k 0.6× | 2.5k 0.6× | 2.4k 1.3× | 816 0.7× | 989 0.9× | 267 | 8.3k | ||
| Marina Chiara Garassino Italy | 46 | 7.5k 1.4× | 6.4k 1.5× | 2.4k 1.3× | 818 0.7× | 1.5k 1.3× | 309 | 10.6k | ||
| Anthony Elias United States | 50 | 5.9k 1.1× | 3.5k 0.8× | 2.2k 1.2× | 735 0.6× | 2.0k 1.7× | 205 | 9.8k |
Countries citing papers authored by David E. Gerber
Since
Specialization
Citations
This map shows the geographic impact of David E. Gerber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Gerber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Gerber more than expected).
Fields of papers citing papers by David E. Gerber
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by David E. Gerber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Gerber. The network helps show where David E. Gerber may publish in the future.
Co-authorship network of co-authors of David E. Gerber
This figure shows the co-authorship network connecting the top 25 collaborators of David E. Gerber. A scholar is included among the top collaborators of David E. Gerber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Gerber. David E. Gerber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Itzstein, Mitchell S. von, Suzanne E. Dahlberg, David E. Gerber, et al.. (2025). Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer. The Oncologist. 30(3).
2.
Lee, Jessica L., Ang Gao, Navid Sadeghi, et al.. (2025). Implementation of a Patient Navigation Program to Support Representative Participation in Cancer Clinical Trials. Cancer Medicine. 14(15). e71125–e71125.
3.
Bhalla, Sheena, Jessica L. Lee, Hong Zhu, et al.. (2024). Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable Populations. Journal of the National Comprehensive Cancer Network. 22(3). 151–157.
4.
Itzstein, Mitchell S. von, Timothy F. Burns, Jonathan E. Dowell, et al.. (2024). Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS -Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 31(4). 639–648.
5.
Iyengar, Puneeth, Chen Hu, Daniel R. Gomez, et al.. (2024). NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8506–8506.
6.
Itzstein, Mitchell S. von, Timothy F. Burns, Jonathan E. Dowell, et al.. (2024). Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8597–8597.
7.
Lee, Simon J. Craddock, Jessica L. Lee, Hong Zhu, et al.. (2023). Assessing Barriers and Facilitators to Lung Cancer Screening: Initial Findings from a Patient Navigation Intervention. Population Health Management. 26(3). 177–184.
8.
Padda, Sukhmani K., Mary W. Redman, David E. Gerber, et al.. (2023). ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 41(16_suppl). TPS9143–TPS9143.
9.
Murphy, Caitlin C., et al.. (2023). An Updated Report on the Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer in the Surveillance, Epidemiology, and End Results Program. JAMA Oncology. 9(8). 1147–1147.
10.
Ostmeyer, Jared, Jason Y. Park, Mitchell S. von Itzstein, et al.. (2023). T-cell tolerant fraction as a predictor of immune-related adverse events. Journal for ImmunoTherapy of Cancer. 11(8). e006437–e006437.
11.
Spira, Alexander I., Mark Stewart, Suzanne F. Jones, et al.. (2021). Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group. Clinical Cancer Research. 27(9). 2416–2423.
12.
Hsiehchen, David, Magdalena Espinoza, David E. Gerber, & Muhammad Shaalan Beg. (2021). Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay. Cancer Biology & Therapy. 22(7-9). 455–464.
13.
Gerber, David E., Heidi Hamann, Noel Santini, et al.. (2020). Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial. Clinical Lung Cancer. 21(4). 326–332.
14.
Motea, Edward A., Xiumei Huang, Jessica A. Kilgore, et al.. (2019). NQO1-dependent, Tumor-selective Radiosensitization of Non–small Cell Lung Cancers. Clinical Cancer Research. 25(8). 2601–2609.
15.
Murphy, Caitlin C., Simon J. Craddock Lee, David E. Gerber, et al.. (2019). Patient and provider perspectives on delivery of oral cancer therapies. Patient Education and Counseling. 102(11). 2102–2109.
16.
Yang, Lin, Shidan Wang, David E. Gerber, et al.. (2018). Main bronchus location is a predictor for metastasis and prognosis in lung adenocarcinoma: A large cohort analysis. Lung Cancer. 120. 22–26.
17.
Gerber, David E., et al.. (2016). ALK alterations and inhibition in lung cancer. Seminars in Cancer Biology. 42. 81–88.
18.
Cenik, Bercin Kutluk, Katherine T. Ostapoff, David E. Gerber, & Rolf A. Brekken. (2013). BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer. Molecular Cancer Therapeutics. 12(6). 992–1001.
19.
Iyengar, Puneeth & David E. Gerber. (2013). Locally Advanced Lung Cancer. The Cancer Journal. 19(3). 247–262.
20.
Gerber, David E., Puja Gupta, Michael T. Dellinger, et al.. (2012). Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts. Molecular Cancer Therapeutics. 11(11). 2473–2482.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Bhumsuk Keam Breakdown of academic impact, for papers by Sumithra J. Mandrekar Breakdown of academic impact, for papers by Taofeek K. Owonikoko Breakdown of academic impact, for papers by Rajeshwari Sridhara Breakdown of academic impact, for papers by Joachim G.J.V. Aerts Breakdown of academic impact, for papers by Stephen V. Liu Breakdown of academic impact, for papers by Jeffrey Crawford Breakdown of academic impact, for papers by Zhengjia Chen Breakdown of academic impact, for papers by Marina Chiara Garassino Breakdown of academic impact, for papers by Anthony Elias